The condition, called metabolic dysfunction-associated steatohepatitis, or MASH, is a difficult-to-treat disease that affects ...

Novartis (NVS) announced positive safety and efficacy results from the Phase III program for investigational intrathecal onasemnogene abeparvovec, ...